BElimumab corticoSteroids Sparing Treatment in Systemic Lupus Erythematosus

BELIMUMAB, anti-BLyS human monoclonal antibody, is the first immunotherapy used for the treatment of systemic lupus erythematosus (SLE) which was licensed in 2011 in France.Currently, Belimumab is reimbursed for the treatment of active SLEwith autoantibody-positive after intolerant or initial failure of first-line traitment (anti malaria, non-steroidal anti-inflammatory drugs, glucocorticoids and/ou immunomodulatory agents).EUropean League Against Rheumatism (EULAR) suggest the following terminology of "low dose" when steroids are less than 7.5 mg/day (prednisone equivalent) because this dose range is often used for maintenance therapy for many rheumatic diseases requiring glucocorticoids and it is relatively few adverse effects.In patients with SLE, a significant proportion of the damage could be attributed to corticosteroid therapy, and this damage accumulated over time.Thanks to randomised and subgroups trials, post-hoc analysis , BELIMUMAB seems to be interesting in the maintain of lowest possible dose of glucocorticoids. However, these studies were not design with this aim, so it is impossible to conclude.Thus, BELIMUMAB seems to be very interesting treatment to redcuce glucocorticoids level.We conduce a multicentric French study in real-life settings, to assess the ability of belimumab to achieve low-dose of steroids.

Inclusion Criteria:person aged ≥ 18 yearswith SLE according to ACR/EULAR criteria 2019started treatment by BELIMUMAB between 13 / July / 2011 to 13 / July / 2020following in an hospital center in Poitiers, La Rochelle, Rochefort, Niort, Angoulême, Nantes, Rennes, Tours, Angersaffiliate or beneficiary of a social security schemeExclusion Criteria:Persons Under guardianship or curatorship or without civil lawPregnant and breastfeedingPersons who refused to participatePatients who stoppped BELIMUMAB before 6 months